These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 4568066)
1. The management of obesity. Court JM Drugs; 1972; 4(5):411-8. PubMed ID: 4568066 [No Abstract] [Full Text] [Related]
2. [Research and experience with fenfluramine in obesity]. Pawan GS Vie Med Can Fr; 1973 May; 2(5):415-22. PubMed ID: 4732200 [No Abstract] [Full Text] [Related]
3. A double-blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combination. Weintraub M; Hasday JD; Mushlin AI; Lockwood DH Arch Intern Med; 1984 Jun; 144(6):1143-8. PubMed ID: 6375610 [TBL] [Abstract][Full Text] [Related]
6. A comparative trial of fenfluramine and diethylpropion inbesity. Silverstone JT; Cooper RM; Begg RR Br J Clin Pract; 1970 Oct; 24(10):423-5. PubMed ID: 4923926 [No Abstract] [Full Text] [Related]
7. A comparative trial of fenfluramine and diethylpropion in obese, hypertensive patients. Follows OJ Br J Clin Pract; 1971 May; 25(5):236-8. PubMed ID: 4931755 [No Abstract] [Full Text] [Related]
8. The current status of antiobesity drugs. Galloway SM; Farquhar DL; Munro JF Postgrad Med J; 1984; 60 Suppl 3():19-26. PubMed ID: 6393107 [TBL] [Abstract][Full Text] [Related]
9. The management of obesity: some recent concepts. Weinhaus RS Mo Med; 1969 Sep; 66(9):719-23 passim. PubMed ID: 4897933 [No Abstract] [Full Text] [Related]
10. [Therapy of obesity]. Hofmann GG Med Klin; 1976 Jun; 71(23):971-9. PubMed ID: 933996 [No Abstract] [Full Text] [Related]
11. Long-term use of diethylpropion in obesity. McKay RH Curr Med Res Opin; 1973; 1(8):489-93. PubMed ID: 4589633 [No Abstract] [Full Text] [Related]
12. Long-term drug treatment of obesity in a private practice setting. Atkinson RL; Blank RC; Schumacher D; Dhurandhar NV; Ritch DL Obes Res; 1997 Nov; 5(6):578-86. PubMed ID: 9449143 [TBL] [Abstract][Full Text] [Related]
13. Long-term weight control study. IV (weeks 156 to 190). The second double-blind phase. Weintraub M; Sundaresan PR; Schuster B; Averbuch M; Stein EC; Cox C; Byrne L Clin Pharmacol Ther; 1992 May; 51(5):608-14. PubMed ID: 1587075 [TBL] [Abstract][Full Text] [Related]
14. Obesity--the health hazard of our time. Sedgwick JP S Afr Med J; 1971 Apr; 45(14):362-70. PubMed ID: 4930511 [No Abstract] [Full Text] [Related]
15. Long-term weight control study. III (weeks 104 to 156). An open-label study of dose adjustment of fenfluramine and phentermine. Weintraub M; Sundaresan PR; Schuster B; Moscucci M; Stein EC Clin Pharmacol Ther; 1992 May; 51(5):602-7. PubMed ID: 1587074 [TBL] [Abstract][Full Text] [Related]
16. Anorexigenic drugs in perspective. Fineberg SK J Am Geriatr Soc; 1967 Jan; 15(1):51-8. PubMed ID: 6015545 [No Abstract] [Full Text] [Related]
17. Long-term weight control study. II (weeks 34 to 104). An open-label study of continuous fenfluramine plus phentermine versus targeted intermittent medication as adjuncts to behavior modification, caloric restriction, and exercise. Weintraub M; Sundaresan PR; Schuster B; Ginsberg G; Madan M; Balder A; Stein EC; Byrne L Clin Pharmacol Ther; 1992 May; 51(5):595-601. PubMed ID: 1587073 [TBL] [Abstract][Full Text] [Related]
18. Controlled-release diethylpropion hydrochloride used in a program for weight reduction. Parsons WB Clin Ther; 1981; 3(5):329-35. PubMed ID: 7471128 [TBL] [Abstract][Full Text] [Related]
19. Drugs in obesity. Sapeika N S Afr Med J; 1974 Oct; 48(48):2027-30. PubMed ID: 4439101 [No Abstract] [Full Text] [Related]